2018 American Transplant Congress
Identifying Patients with CPRA>99.95% Likely to Be Offered Deceased Donor Kidneys
Emory Transplant Center, Atlanta, GA.
The implementation of the new kidney allocation system and priority of kidneys for cPRA=100% subjects revealed a hierarchy difference in allocation to patients with cPRA=99.45%-100%.…2018 American Transplant Congress
Approaches to Prevention of Antibody Rebound after HLA Sensitization in a Mouse Model
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Control of donor specific antibodies (DSA) is critical for prevention of antibody mediated rejection (ABMR). Removal of DSAs with PLEX often results in significant…2018 American Transplant Congress
Development of Post-Transplant DSA Following Immunosuppression Minimization/Withdrawal in Liver Transplant Recipients
Despite the allograft-risk associated with DSA, the development of post-transplant HLA donor-specific antibody (DSA) is not well described in liver transplant (LT) patients undergoing immunosuppression…2018 American Transplant Congress
Impact of Pretransplant Donor-Specific Antibodies on Kidney Allograft Recipients with Negative Flow Cytometry Crossmatches
Asan Medical Center, Seoul, Korea.
This study evaluated the impact of DSA on clinical outcomes in KT recipients negative on FCXM. Of 575 consecutive patients who underwent living donor KT…2018 American Transplant Congress
IgG De Novo HLA Antibody Subclass Analysis in Patients Undergoing Allograft Nephrectomy after Transplant Failure
Introduction: different immunising events can stimulate the production of disparate antibody subclass profiles, reflecting a diverse extent of T-cell activation. Transplant nephrectomy (NX) is a…2017 American Transplant Congress
Post-Transplant Reduction in Pre-Existing Donor-Specific Antibody Levels After Belatacept- vs Cyclosporine-Based Immunosuppression.
1Emory University, Atlanta, GA; 2Bristol-Myers Squibb, Lawrenceville, NJ
Purpose: We explored the effect of belatacept (bela)- and cyclosporine (CsA)-based immunosuppression (IS) on pre-existing donor-specific antibody (DSA) levels by mean fluorescence intensity (MFI) in…2017 American Transplant Congress
Development of De Novo Donor Specific Antibodies (dnDSAs) Not the Presence of Pre-Transplant Donor Specific Antibodies (Pre-DSAs) Increase Rejection Risk in Crossmatch Negative Kidney Transplant Recipients.
Mayo Clinic Arizona, Phoenix, AZ
Aim: Study the impact of Pre-DSAs on allograft outcomes in crossmatch negative kidney transplant recipients.Methods: Single center retrospective analysis of characteristics and outcomes of kidney…2017 American Transplant Congress
Characterization of De Novo Donor-Specific HLA Antibodies and Correlations with C4d+ Antibody-Mediated Rejection of Kidney Transplants.
Aim: Characteristics of de novo donor-specific HLA antibodies (dnDSA) that are associated with C4d positive antibody-mediated rejection (C4d+ AMR) in kidney transplants have not been…2017 American Transplant Congress
HLA Alloimmunization According to the Different Immunization Events and Consequences on Access to Kidney Transplantation.
Patients awaiting solid organ transplantation may develop anti-HLA antibodies after sensitization events such as transfusions, pregnancies or previous transplantations. The aim of our work was…2017 American Transplant Congress
Influence of Donor-Specific Antibodies on Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Llobregat Catalunya, Spain; 2Novartis Pharma AG, Basel, Switzerland
Purpose: The development of donor-specific antibody (DSA) is a known risk factor for poor graft outcomes after kidney transplantation (KTx). Previous analysis of the ELEVATE…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 47
- Next Page »